These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 35099012)

  • 1. Lassa Virus Replicon Particle Vaccine Protects Strain 13/N Guinea Pigs Against Challenge With Geographically and Genetically Diverse Viral Strains.
    Spengler JR; Kainulainen MH; Welch SR; Coleman-McCray JD; Harmon JR; Condrey JA; Scholte FEM; Nichol ST; Montgomery JM; Albariño CG; Spiropoulou CF
    J Infect Dis; 2022 Nov; 226(9):1545-1550. PubMed ID: 35099012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A recombinant vesicular stomatitis virus-based Lassa fever vaccine protects guinea pigs and macaques against challenge with geographically and genetically distinct Lassa viruses.
    Safronetz D; Mire C; Rosenke K; Feldmann F; Haddock E; Geisbert T; Feldmann H
    PLoS Negl Trop Dis; 2015 Apr; 9(4):e0003736. PubMed ID: 25884628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Lassa Virus Live-Attenuated Vaccine Candidate Based on Rearrangement of the Intergenic Region.
    Cai Y; Iwasaki M; Motooka D; Liu DX; Yu S; Cooper K; Hart R; Adams R; Burdette T; Postnikova EN; Kurtz J; St Claire M; Ye C; Kuhn JH; Martínez-Sobrido L; de la Torre JC
    mBio; 2020 Mar; 11(2):. PubMed ID: 32209677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Lassa Fever Live-Attenuated Vaccine Based on Codon Deoptimization of the Viral Glycoprotein Gene.
    Cai Y; Ye C; Cheng B; Nogales A; Iwasaki M; Yu S; Cooper K; Liu DX; Hart R; Adams R; Brady T; Postnikova EN; Kurtz J; St Claire M; Kuhn JH; de la Torre JC; Martínez-Sobrido L
    mBio; 2020 Feb; 11(1):. PubMed ID: 32098811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protection From Lethal Lassa Disease Can Be Achieved Both Before and After Virus Exposure by Administration of Single-Cycle Replicating Lassa Virus Replicon Particles.
    Kainulainen MH; Spengler JR; Welch SR; Coleman-McCray JD; Harmon JR; Scholte FEM; Goldsmith CS; Nichol ST; Albariño CG; Spiropoulou CF
    J Infect Dis; 2019 Sep; 220(8):1281-1289. PubMed ID: 31152662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lethal Infection of Lassa Virus Isolated from a Human Clinical Sample in Outbred Guinea Pigs without Adaptation.
    Maruyama J; Manning JT; Mateer EJ; Sattler R; Bukreyeva N; Huang C; Paessler S
    mSphere; 2019 Sep; 4(5):. PubMed ID: 31554720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alphavirus vector-based replicon particles expressing multivalent cross-protective Lassa virus glycoproteins.
    Wang M; Jokinen J; Tretyakova I; Pushko P; Lukashevich IS
    Vaccine; 2018 Jan; 36(5):683-690. PubMed ID: 29287681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A recombinant VSV-vectored vaccine rapidly protects nonhuman primates against heterologous lethal Lassa fever.
    Cross RW; Woolsey C; Prasad AN; Borisevich V; Agans KN; Deer DJ; Geisbert JB; Dobias NS; Fenton KA; Geisbert TW
    Cell Rep; 2022 Jul; 40(3):111094. PubMed ID: 35858566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A ML29 reassortant virus protects guinea pigs against a distantly related Nigerian strain of Lassa virus and can provide sterilizing immunity.
    Carrion R; Patterson JL; Johnson C; Gonzales M; Moreira CR; Ticer A; Brasky K; Hubbard GB; Moshkoff D; Zapata J; Salvato MS; Lukashevich IS
    Vaccine; 2007 May; 25(20):4093-102. PubMed ID: 17360080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA vaccines elicit durable protective immunity against individual or simultaneous infections with Lassa and Ebola viruses in guinea pigs.
    Cashman KA; Wilkinson ER; Wollen SE; Shamblin JD; Zelko JM; Bearss JJ; Zeng X; Broderick KE; Schmaljohn CS
    Hum Vaccin Immunother; 2017 Dec; 13(12):3010-3019. PubMed ID: 29135337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of a Scalable Replicon-Particle Vaccine to Protect Against Lethal Lassa Virus Infection in the Guinea Pig Model.
    Kainulainen MH; Spengler JR; Welch SR; Coleman-McCray JD; Harmon JR; Klena JD; Nichol ST; Albariño CG; Spiropoulou CF
    J Infect Dis; 2018 May; 217(12):1957-1966. PubMed ID: 29800368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses.
    Pushko P; Geisbert J; Parker M; Jahrling P; Smith J
    J Virol; 2001 Dec; 75(23):11677-85. PubMed ID: 11689649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lassa virus-like particles displaying all major immunological determinants as a vaccine candidate for Lassa hemorrhagic fever.
    Branco LM; Grove JN; Geske FJ; Boisen ML; Muncy IJ; Magliato SA; Henderson LA; Schoepp RJ; Cashman KA; Hensley LE; Garry RF
    Virol J; 2010 Oct; 7():279. PubMed ID: 20961433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adenoviral vector-based vaccine is fully protective against lethal Lassa fever challenge in Hartley guinea pigs.
    Maruyama J; Mateer EJ; Manning JT; Sattler R; Seregin AV; Bukreyeva N; Jones FR; Balint JP; Gabitzsch ES; Huang C; Paessler S
    Vaccine; 2019 Oct; 37(45):6824-6831. PubMed ID: 31561999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Temporal Progression of Lesions in Guinea Pigs Infected With Lassa Virus.
    Bell TM; Shaia CI; Bearss JJ; Mattix ME; Koistinen KA; Honnold SP; Zeng X; Blancett CD; Donnelly GC; Shamblin JD; Wilkinson ER; Cashman KA
    Vet Pathol; 2017 May; 54(3):549-562. PubMed ID: 28438110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The broad-spectrum antiviral favipiravir protects guinea pigs from lethal Lassa virus infection post-disease onset.
    Safronetz D; Rosenke K; Westover JB; Martellaro C; Okumura A; Furuta Y; Geisbert J; Saturday G; Komeno T; Geisbert TW; Feldmann H; Gowen BB
    Sci Rep; 2015 Oct; 5():14775. PubMed ID: 26456301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccine platforms to control Lassa fever.
    Lukashevich IS; Pushko P
    Expert Rev Vaccines; 2016 Sep; 15(9):1135-50. PubMed ID: 27136941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A DNA vaccine delivered by dermal electroporation fully protects cynomolgus macaques against Lassa fever.
    Cashman KA; Wilkinson ER; Shaia CI; Facemire PR; Bell TM; Bearss JJ; Shamblin JD; Wollen SE; Broderick KE; Sardesai NY; Schmaljohn CS
    Hum Vaccin Immunother; 2017 Dec; 13(12):2902-2911. PubMed ID: 29045192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity of a protective intradermal DNA vaccine against lassa virus in cynomolgus macaques.
    Jiang J; Banglore P; Cashman KA; Schmaljohn CS; Schultheis K; Pugh H; Nguyen J; Humeau LM; Broderick KE; Ramos SJ
    Hum Vaccin Immunother; 2019; 15(9):2066-2074. PubMed ID: 31071008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Vaccine Platform against Arenaviruses Based on a Recombinant Hyperattenuated Mopeia Virus Expressing Heterologous Glycoproteins.
    Carnec X; Mateo M; Page A; Reynard S; Hortion J; Picard C; Yekwa E; Barrot L; Barron S; Vallve A; Raoul H; Carbonnelle C; Ferron F; Baize S
    J Virol; 2018 Jun; 92(12):. PubMed ID: 29593043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.